A Machine Learning-Driven Approach to Overcome On-Target, Off-Tumour Toxicity in Multispecific Antibodies Using Avidity-Driven Selectivity
Time: 1:45 pm
day: Day 2
Details:
- Combining high-throughput experimentation with ML to co-optimise multispecifics for function and developability
- Discovering HER2xCD3 TCEs with killing selectivity corresponding to >400-fold improvement versus clinical benchmarks
- Developing a pipeline of highly selective VHH-based TCEs against targets with TAA expression differences of 3-fold between health and diseased cell lines
